- Home
- PAXS vs CTNM Comparison
PAXS vs CTNM Comparison
Compare PAXS & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PAXS | CTNM |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 664.0M | 550.7M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | PAXS | CTNM |
|---|---|---|
| Price | $14.07 | $17.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 200.1K | ★ 534.3K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.74 | $8.60 |
| 52 Week High | $16.56 | $17.51 |
Technical Indicators
Market Signals| Indicator | PAXS | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 49.63 | 62.30 |
| Support Level | $13.89 | $13.65 |
| Resistance Level | $14.24 | N/A |
| Average True Range (ATR) | 0.15 | 0.86 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 35.68 | 96.43 |
Price Performance
Historical ComparisonAbout PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.